News & Press Releases
Filter by:
Welcome to ‘Web3.’ What’s That?
December 6, 2021
Mintz Member Frank Gerratana was quoted in a special edition of The New York Times DealBook newsletter explaining "Web3," which crypto enthusiasts see as the future of an internet run on blockchain-based tokens. In the article, Mr. Gerratana addressed intellectual property considerations associated with non-fungible tokens, or NFTs, and shared how some of his clients are preparing to adopt this technology.
How I Made Managing Partner: 'My Colleagues Admired My Collaborative Approach,' Says Bob Bodian of Mintz
December 6, 2021
Mintz Managing Member Bob Bodian was featured in Law.com’s “How I Made It” Q&A series, which spotlights career advancement stories and offers career advice from industry leaders. In the profile piece, Mr. Bodian shared his legal career journey culminating in his appointment as Managing Member of Mintz, keys to successful business development, advice for his younger self, firm initiatives he is most proud of, and more.
Science-Based Definition Of US Waters Won't Pass In Court
December 3, 2021
Mintz Member and Chair of the firm’s Environmental Law Practice Jeff Porter authored a Law360 Expert Analysis column examining the U.S. Environmental Protection Agency (EPA)’s and the U.S. Army Corps of Engineers (Corps)’ most recent proposed definition of "Waters of the United States." In the article, Mr. Porter discussed the legal challenges EPA, the Corps, and property owners face going forward.
Top White Collar Lawyers 2021: Randy K. Jones
December 1, 2021
Mintz Member Randy Jones was featured as one of the 2021 "Top White Collar Lawyers" in California by the Daily Journal. The article highlighted Mr. Jones' career successes and current roster of cases.
As ANDA Suit Venue Options Shrink, Del., NJ Rule For Now
November 29, 2021
Mintz Members Peter Cuomo and Adam Samansky and Associate Joseph Rutkowski were quoted in an article published by Law360 on the potential implications of the Federal Circuit’s recent ruling in Celgene Corp. v. Mylan Pharmaceuticals Inc., which cemented a prior decision in Valeant v. Mylan holding that patent suits against generic drugmakers must be filed where the company is incorporated or where it performed actions related to its Abbreviated New Drug Application.
